Bagher Seyedalipour | Biochemistry Award | Best Researcher Award

Assoc. Prof. Dr. Bagher Seyedalipour | Biochemistry Award | Best Researcher Award

Biochemistry, University of Mazandaran, Iran

 

Assoc. Prof. Dr. Bagher Seyedalipour is a distinguished biochemist at the University of Mazandaran, specializing in protein engineering and proteomics. With a Ph.D. from Tehran University, he teaches and conducts advanced research on protein structures and gene manipulation techniques, especially using recombinant DNA. His laboratory focuses on creating therapeutic proteins, like luciferase and superoxide dismutase, exploring their functions and effects through site-directed mutagenesis. Dr. Seyedalipour’s work advances understanding of pathogenic mutations, contributing significantly to molecular biology and therapeutic biochemistry. 🔬🧬

 

Publication Profile

Scopus

Orcid

Academic Background

Dr. Bagher Seyedalipour is an accomplished biochemist with a profound dedication to academic research and teaching. He has developed an extensive foundation in the field of biochemistry through his rigorous education and current academic pursuits at the University of Mazandaran.

Education and Qualifications

Dr. Seyedalipour’s academic journey began with a Bachelor of Science in Biology from Shahid Beheshti University, Tehran. He furthered his expertise with a Master’s degree in Biochemistry from Tarbiat Modares University, followed by a Ph.D. in Biochemistry from the Institute of Biochemistry and Biophysics at Tehran University. His extensive training equips him with in-depth knowledge across biochemical sciences, particularly in protein engineering and molecular biology.

Teaching and Research Interests

Dr. Seyedalipour teaches courses on Biochemistry, Structure, Metabolism, and Advanced Molecular Biology for undergraduate and graduate students. His laboratory is primarily focused on Enzymology, Protein Engineering, and Proteomics, aiming to characterize and manipulate genes using recombinant DNA technology. His research highlights include the expression and production of therapeutic proteins, such as luciferase, superoxide dismutase, and uricase, where he applies site-directed mutagenesis for mutation analysis and to explore mutation-pathogenicity relationships.

Conclusion

Dr. Bagher Seyedalipour is a strong candidate for the Research for Best Researcher Award. His work in biochemistry, particularly his focus on protein engineering and pathogenic mutation analysis, stands out in its potential impact on therapeutic advancements and our understanding of molecular biology.

Publication Top Notes  

  • 🧬 “Mutation/metal deficiency in the electrostatic loop enhanced aggregation process in apo/holo SOD1 variants: implications for ALS diseases,” Ashkaran, F., Seyedalipour, B., et al. – BMC Chemistry (2024)
  • 🧬 “Implications of ALS-Associated Mutations on Biochemical and Biophysical Features of hSOD1 and Aggregation Formation,” Mohammadi, S., Seyedalipour, B., et al. – Biochemical Genetics (2024), 1 citation
  • 🧬 “GSTP1-A313G genetic polymorphism and the risk of preeclampsia in pregnant women: A study in the northern population of Iran,” Jalalian, E.J., Seyedalipour, B., et al. – Pregnancy Hypertension (2024)s
  • 🧬 “1,4-Diol Hq (TBHQ) vs 1,4-dithiol (TBDT); simulation of safe antioxidant with a lower carcinogenic activity,” Mosavi, S.Z., Seyedalipour, B., et al. – Science Progress (2024)
  • 🧬 “Exploring the anti-amyloid potential of salvianolic acid A against the ALS-associated mutant SOD1,” Waheed, Z.A., Seyedalipour, B., et al. – Molecular Simulation (2024), 1 citation
  • 🧬 “Catharanthine, an anticancer vinca alkaloid: in silico and in vitro analysis of the autophagic system,” Gholami, F., Seyedalipour, B., et al. – Naunyn-Schmiedeberg’s Archives of Pharmacology (2024)
  • 🧬 “Polyphenolic flavonoid compounds as inhibitors of aggregation in FALS-associated D101G SOD1 mutant,” Qassim, H.M., Seyedalipour, B., et al. – Computational Biology and Chemistry (2023), 4 citations
  • 🧬 “Role of charged residues of the “electrostatic loop” of hSOD1 in aggregation under amyloidogenic conditions,” Mavadat, E., Seyedalipour, B., et al. – International Journal of Biological Macromolecules (2023), 6 citations
  • 🧬 “A double point mutation of SOD1 targeting net charge promotes aggregation,” Mavadat, E., Seyedalipour, B., et al. – Biochimica et Biophysica Acta (2023), 5 citations
  • 🧬 “Sensitive determination of urea in luciferin chemiluminescence system,” Nemati, A., Seyedalipour, B., et al. – Chemical Papers (2023), 1 citation

 

 

Sonia Hermoso Durán | Biochemistry | Women Researcher Award

Sonia Hermoso Durán | Biochemistry | Women Researcher Award

Dr Sonia Hermoso Durán, Universidad de Zaragoza, Spain

Dr. Sonia Hermoso Durán is a highly accomplished researcher in the field of biochemistry and molecular biology. Her extensive work experience, particularly as a predoctoral fellow at Aragón Health Research Institute, coupled with her advanced education in biochemistry and molecular biology, makes her a strong candidate for the Women Researcher Award.

Publication Profile

Google Scholar

Work Experience

Dr. Hermoso Durán has been a Predoctoral Fellow at the Aragón Health Research Institute (IIS Aragón) from January 2020 to June 2024, funded by a prestigious P-FIS grant from the Carlos III Health Institute. She also served as a Senior Research Technician on critical clinical research projects focused on digestive tumors and colon cancer.

Educational Background

Dr. Hermoso Durán is completing her PhD in Biochemistry and Molecular Biology at the University of Zaragoza. She holds a Specialist degree in Laboratory Medicine, with further education in applied statistics and machine learning for clinical laboratory applications.

Research Stays

Dr. Hermoso Durán has completed research stays in top international research institutions, including the Kolling Institute in Sydney, Australia, and the Cancer Research Center of Marseille, where she gained significant experience in cancer research.

Publications

Dr. Hermoso Durán has published several notable studies, including research on the development of machine learning models for diagnosing pancreatic cancer from serum samples, published in Advanced Intelligent Systems. Other studies include contributions to colorectal cancer diagnostics and investigations on the potential use of thermal liquid biopsy for multiple sclerosis detection.

Grants and Conferences

She has obtained multiple research grants, including those from the Carlos III Health Institute and Aragón Health Research Institute, supporting her stays in renowned research centers. Additionally, Dr. Hermoso Durán has delivered oral talks at prestigious conferences such as the European Pancreatic Club and Spanish Gastroenterology Association.

Publication Top Notes

Estudio de la ferropenia en el laboratorio clínico

False-positive fecal immunochemical test results in colorectal cancer screening and gastrointestinal drug use

Thermal liquid biopsy (TLB) focused on benign and premalignant pancreatic cyst diagnosis

Vertical cutoff methods in serum protein electrophoresis for the measurement of monoclonal protein concentrations: Which is best?

Thermal liquid biopsy (TLB) of blood plasma as a potential tool to help in the early diagnosis of multiple sclerosis

Fluorescence liquid biopsy for cancer detection is improved by using cationic dendronized hyperbranched polymer

Bowel preparation for colonoscopy changes serum composition as detected by thermal liquid biopsy and fluorescence spectroscopy

Conclusion

Dr. Sonia Hermoso Durán’s extensive research background, numerous grants, high-impact publications, and recognition through conference presentations clearly demonstrate her qualifications. Her contributions to biochemistry and molecular biology, particularly in cancer diagnostics, make her an outstanding candidate for the Women Researcher Award.